Training in the use of EP was noticeably different compared to other prognostic tests: node-negative and node-positive ER+/HER2− BC patients (n = 964) were included in the multigene algorithm design, and a combined score of EP, tumor size and nodal status (EPclin) was defined in the large training cohort. The gene discussed is ERBB2; the disease is neoplasm.